Omkar Speciality, a Rs.265 crore engaged in speciality chemicals and active pharmaceutical ingredients (APIs), has posted strong net profit growth of 64.1 per cent during the first quarter ended June 2015. Its consolidated net profit moved up to Rs.8.17 crore from Rs.4.97 crore in the corresponding period of last year. Its consolidated net sales went up by 69.1 per cent to Rs.90.48 crore from Rs.53.51 crore. EBIDTA improved by 97 per cent to Rs.17.62 crore from Rs.8.95 crore. EPS worked out to Rs.3.97 as against Rs.2.53 in the last period.
Omkar Herlekar, the whole time director, said, “It is great to start off this fiscal year with a robust increase in our top-line with the commencement of operations of the additional capacity at Chiplun. We believe traction in sales to continue over the coming quarters with a steady improvement in capacity utilization. The margins have increased because of higher composition of speciality chemicals and APIs in the total sales.”
The company has nine units with over 1,100 workforce. It has an installed capacity of 4,920 MT per annum. It product segments include lodine compounds, selenium compounds, intermediates, resolving agents, veterinary growth enhancers and APIs which comprises of more than 200 products.